Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/RIPK1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RIPK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/RIPK1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RIPK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190288210 | Endometrium | AEH | regulation of response to oxidative stress | 20/2100 | 98/18723 | 5.64e-03 | 3.46e-02 | 20 |
GO:00072546 | Endometrium | AEH | JNK cascade | 30/2100 | 167/18723 | 6.16e-03 | 3.70e-02 | 30 |
GO:00181058 | Endometrium | AEH | peptidyl-serine phosphorylation | 50/2100 | 315/18723 | 7.20e-03 | 4.13e-02 | 50 |
GO:00228986 | Endometrium | AEH | regulation of transmembrane transporter activity | 45/2100 | 278/18723 | 7.34e-03 | 4.18e-02 | 45 |
GO:200123317 | Endometrium | EEC | regulation of apoptotic signaling pathway | 91/2168 | 356/18723 | 1.31e-13 | 3.28e-11 | 91 |
GO:000697917 | Endometrium | EEC | response to oxidative stress | 99/2168 | 446/18723 | 9.02e-11 | 1.13e-08 | 99 |
GO:006219717 | Endometrium | EEC | cellular response to chemical stress | 77/2168 | 337/18723 | 2.87e-09 | 2.10e-07 | 77 |
GO:000030217 | Endometrium | EEC | response to reactive oxygen species | 57/2168 | 222/18723 | 4.04e-09 | 2.82e-07 | 57 |
GO:004254216 | Endometrium | EEC | response to hydrogen peroxide | 41/2168 | 146/18723 | 4.12e-08 | 2.29e-06 | 41 |
GO:200123516 | Endometrium | EEC | positive regulation of apoptotic signaling pathway | 37/2168 | 126/18723 | 5.23e-08 | 2.83e-06 | 37 |
GO:200123417 | Endometrium | EEC | negative regulation of apoptotic signaling pathway | 53/2168 | 224/18723 | 2.53e-07 | 1.09e-05 | 53 |
GO:009719117 | Endometrium | EEC | extrinsic apoptotic signaling pathway | 52/2168 | 219/18723 | 2.91e-07 | 1.20e-05 | 52 |
GO:200123617 | Endometrium | EEC | regulation of extrinsic apoptotic signaling pathway | 40/2168 | 151/18723 | 3.33e-07 | 1.33e-05 | 40 |
GO:005140314 | Endometrium | EEC | stress-activated MAPK cascade | 55/2168 | 239/18723 | 3.98e-07 | 1.56e-05 | 55 |
GO:003459917 | Endometrium | EEC | cellular response to oxidative stress | 63/2168 | 288/18723 | 4.05e-07 | 1.58e-05 | 63 |
GO:003109814 | Endometrium | EEC | stress-activated protein kinase signaling cascade | 56/2168 | 247/18723 | 5.25e-07 | 2.00e-05 | 56 |
GO:003287214 | Endometrium | EEC | regulation of stress-activated MAPK cascade | 46/2168 | 192/18723 | 1.06e-06 | 3.56e-05 | 46 |
GO:007030214 | Endometrium | EEC | regulation of stress-activated protein kinase signaling cascade | 46/2168 | 195/18723 | 1.67e-06 | 5.12e-05 | 46 |
GO:004341011 | Endometrium | EEC | positive regulation of MAPK cascade | 89/2168 | 480/18723 | 4.21e-06 | 1.08e-04 | 89 |
GO:004312216 | Endometrium | EEC | regulation of I-kappaB kinase/NF-kappaB signaling | 53/2168 | 249/18723 | 7.59e-06 | 1.73e-04 | 53 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513126 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
hsa0513226 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
hsa0513026 | Endometrium | AEH | Pathogenic Escherichia coli infection | 50/1197 | 197/8465 | 1.72e-05 | 1.86e-04 | 1.36e-04 | 50 |
hsa0516924 | Endometrium | AEH | Epstein-Barr virus infection | 42/1197 | 202/8465 | 5.72e-03 | 3.05e-02 | 2.23e-02 | 42 |
hsa0421010 | Endometrium | AEH | Apoptosis | 30/1197 | 136/8465 | 7.72e-03 | 4.05e-02 | 2.96e-02 | 30 |
hsa0517018 | Endometrium | AEH | Human immunodeficiency virus 1 infection | 43/1197 | 212/8465 | 8.19e-03 | 4.22e-02 | 3.09e-02 | 43 |
hsa0516320 | Endometrium | AEH | Human cytomegalovirus infection | 45/1197 | 225/8465 | 8.98e-03 | 4.56e-02 | 3.34e-02 | 45 |
hsa05131111 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
hsa05132112 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
hsa05130112 | Endometrium | AEH | Pathogenic Escherichia coli infection | 50/1197 | 197/8465 | 1.72e-05 | 1.86e-04 | 1.36e-04 | 50 |
hsa05169111 | Endometrium | AEH | Epstein-Barr virus infection | 42/1197 | 202/8465 | 5.72e-03 | 3.05e-02 | 2.23e-02 | 42 |
hsa0421015 | Endometrium | AEH | Apoptosis | 30/1197 | 136/8465 | 7.72e-03 | 4.05e-02 | 2.96e-02 | 30 |
hsa0517019 | Endometrium | AEH | Human immunodeficiency virus 1 infection | 43/1197 | 212/8465 | 8.19e-03 | 4.22e-02 | 3.09e-02 | 43 |
hsa05163110 | Endometrium | AEH | Human cytomegalovirus infection | 45/1197 | 225/8465 | 8.98e-03 | 4.56e-02 | 3.34e-02 | 45 |
hsa0513127 | Endometrium | EEC | Shigellosis | 79/1237 | 247/8465 | 1.80e-12 | 3.95e-11 | 2.95e-11 | 79 |
hsa0513227 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
hsa0513027 | Endometrium | EEC | Pathogenic Escherichia coli infection | 51/1237 | 197/8465 | 1.98e-05 | 2.28e-04 | 1.70e-04 | 51 |
hsa0516925 | Endometrium | EEC | Epstein-Barr virus infection | 47/1237 | 202/8465 | 6.17e-04 | 4.41e-03 | 3.29e-03 | 47 |
hsa0516325 | Endometrium | EEC | Human cytomegalovirus infection | 47/1237 | 225/8465 | 6.17e-03 | 3.12e-02 | 2.33e-02 | 47 |
hsa046687 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RIPK1 | SNV | Missense_Mutation | | c.1237N>T | p.Arg413Cys | p.R413C | Q13546 | protein_coding | deleterious(0) | probably_damaging(0.925) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RIPK1 | SNV | Missense_Mutation | | c.919G>C | p.Glu307Gln | p.E307Q | Q13546 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
RIPK1 | SNV | Missense_Mutation | | c.808N>T | p.Ala270Ser | p.A270S | Q13546 | protein_coding | tolerated(0.38) | benign(0.173) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
RIPK1 | SNV | Missense_Mutation | novel | c.1281N>C | p.Glu427Asp | p.E427D | Q13546 | protein_coding | tolerated(0.41) | benign(0) | TCGA-C8-A132-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RIPK1 | SNV | Missense_Mutation | | c.439N>A | p.Asp147Asn | p.D147N | Q13546 | protein_coding | deleterious(0.03) | probably_damaging(0.987) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD |
RIPK1 | insertion | Frame_Shift_Ins | novel | c.1407_1408insGGTCCTGTGGAGGAGTCCTGGTTTGCTCCTTCCCTGG | p.Ser470GlyfsTer42 | p.S470Gfs*42 | Q13546 | protein_coding | | | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
RIPK1 | SNV | Missense_Mutation | | c.324N>C | p.Met108Ile | p.M108I | Q13546 | protein_coding | tolerated(0.62) | benign(0) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RIPK1 | SNV | Missense_Mutation | | c.1297G>A | p.Glu433Lys | p.E433K | Q13546 | protein_coding | tolerated(0.79) | benign(0.021) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RIPK1 | SNV | Missense_Mutation | rs748885856 | c.1571N>T | p.Pro524Leu | p.P524L | Q13546 | protein_coding | tolerated(0.12) | benign(0) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
RIPK1 | deletion | Frame_Shift_Del | novel | c.1302delN | p.Gly436AlafsTer76 | p.G436Afs*76 | Q13546 | protein_coding | | | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 340590273 | | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565867 | | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178102513 | PONATINIB | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 384403680 | | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | RESVERATROL | RESVERATROL | 16116226 |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 336446940 | | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 354702223 | NECROSTATIN | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | GSK2982772 | | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 354702224 | | |
8737 | RIPK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 354702222 | | |